Tribl G G, Asenbaum S, Happe S, Bonelli R M, Zeitlhofer J, Auff E
Department of Clinical Neurology, University of Vienna, Vienna General Hospital, Austria.
Nucl Med Commun. 2004 Jan;25(1):55-60. doi: 10.1097/00006231-200401000-00008.
Dopaminergic treatment is very effective in restless legs syndrome (RLS) and periodic leg movements in sleep (PLMS). However, neuroreceptor imaging studies that addressed altered striatal dopaminergic function have given controversial results. In this present study, 14 patients with idiopathic RLS (iRLS) and PLMS with a good response to dopaminergic and non-dopaminergic treatment and ten healthy sex- and age-matched controls were investigated off-medication by using 123I-IBZM and SPECT. RLS symptoms and sleep disturbances were evaluated using three nights of polysomnography, the Pittsburgh Sleep Quality Index, and the International RLS Study Group (IRLSSG) rating scale. The patients presented with sleep disturbances, a high PLMS index (56.2 +/- 33.1 per h), and severe RLS symptoms during SPECT (IRLSSG rating scale 23.1 +/- 8.0), and showed no significant differences in striatal to frontal IBZM binding to D2 receptors compared to controls (ratio striatum/frontal cortex, right side 1.60 +/- 0.10 vs 1.63 +/- 0.08, P = 0.35, NS; left side 1.61 +/- 0.11 vs 1.63 +/- 0.08, P = 0.51, NS). These findings show normal function of striatal D2 receptors in successfully treated patients with iRLS and PLMS. Dopaminergic and non-dopaminergic pretreatment does not appear to change striatal D2 receptor binding as compared to healthy controls. Structures other than striatal D2 receptors are discussed as possible causes of the treatment effects in RLS.
多巴胺能治疗对不宁腿综合征(RLS)和睡眠期周期性腿部运动(PLMS)非常有效。然而,针对纹状体多巴胺能功能改变的神经受体成像研究结果存在争议。在本研究中,对14例特发性RLS(iRLS)和PLMS患者进行了研究,这些患者对多巴胺能和非多巴胺能治疗反应良好,同时选取了10名年龄和性别匹配的健康对照者,在停药状态下使用123I-IBZM和单光子发射计算机断层扫描(SPECT)进行检查。使用三晚的多导睡眠图、匹兹堡睡眠质量指数和国际RLS研究组(IRLSSG)评分量表评估RLS症状和睡眠障碍。患者存在睡眠障碍、高PLMS指数(每小时56.2±33.1次),在SPECT检查期间有严重的RLS症状(IRLSSG评分量表评分为23.1±8.0),与对照组相比,纹状体与额叶的IBZM与D2受体结合无显著差异(纹状体/额叶皮质比值,右侧为1.60±0.10 vs 1.63±0.08,P = 0.35,无统计学意义;左侧为1.61±0.11 vs 1.63±0.08,P = 0.51,无统计学意义)。这些发现表明,成功治疗的iRLS和PLMS患者纹状体D2受体功能正常。与健康对照组相比,多巴胺能和非多巴胺能预处理似乎并未改变纹状体D2受体结合。纹状体D2受体以外的结构被讨论为RLS治疗效果的可能原因。